192 related articles for article (PubMed ID: 33037430)
1. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04).
Shimoyama R; Imamura Y; Uryu K; Mase T; Taguri M; Okuda T; Fujimura Y; Hayashi M; Tanaka S; Sawamukai K; Minami H
Jpn J Clin Oncol; 2024 Jan; 54(1):70-80. PubMed ID: 37801431
[TBL] [Abstract][Full Text] [Related]
4. Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study).
Kobayashi S; Wada H; Sakai D; Baba H; Kanai M; Kamachi H; Takayama T; Ueno M; Takahashi M; Sho M; Yoshimura K; Hatano E; Nagano H; Ioka T;
Oncology; 2024; 102(6):447-456. PubMed ID: 38048759
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
6. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
McNamara MG; Goyal L; Doherty M; Springfeld C; Cosgrove D; Sjoquist KM; Park JO; Verdaguer H; Braconi C; Ross PJ; Gramont A; Zalcberg JR; Palmer DH; Valle JW; Knox JJ
Future Oncol; 2020 Jun; 16(16):1069-1081. PubMed ID: 32374623
[TBL] [Abstract][Full Text] [Related]
7. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
[TBL] [Abstract][Full Text] [Related]
8. ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers.
Goetze T; Gonzalez-Carmona MA; Kochen L; Agaoglu NB; Al-Batran SE; Habibzada T; Pons M; Brunner M; Ettrich TJ; Köhne CH; Roderburg C; Modest D
Future Oncol; 2024 Feb; 20(6):307-315. PubMed ID: 38410920
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
10. Current therapy and future directions in biliary tract malignancies.
Ciombor KK; Goff LW
Curr Treat Options Oncol; 2013 Sep; 14(3):337-49. PubMed ID: 23686724
[TBL] [Abstract][Full Text] [Related]
11. Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.
Wheless M; Agarwal R; Goff L; Lockney N; Padmanabhan C; Heumann T
Curr Treat Options Oncol; 2024 Jan; 25(1):127-160. PubMed ID: 38177560
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
Hu YF; Ma WJ; Jin YW; Li FY
Hepatology; 2024 May; 79(5):965-969. PubMed ID: 37870296
[No Abstract] [Full Text] [Related]
13. Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors.
Liu Q; Zhang P; Li Q
Discov Med; 2024 Jan; 36(180):48-60. PubMed ID: 38273745
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
Kish M; Chan K; Perry K; Ko YJ
Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664
[TBL] [Abstract][Full Text] [Related]
15. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy in Biliary Tract Cancers.
Merla A; Liu KG; Rajdev L
Curr Treat Options Oncol; 2015 Oct; 16(10):48. PubMed ID: 26266637
[TBL] [Abstract][Full Text] [Related]
17. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Roth GS; Verlingue L; Sarabi M; Blanc JF; Boleslawski E; Boudjema K; Bretagne-Bignon AL; Camus-Duboc M; Coriat R; Créhange G; De Baere T; de la Fouchardière C; Dromain C; Edeline J; Gelli M; Guiu B; Horn S; Laurent-Croise V; Lepage C; Lièvre A; Lopez A; Manfredi S; Meilleroux J; Neuzillet C; Paradis V; Prat F; Ronot M; Rosmorduc O; Cunha AS; Soubrane O; Turpin A; Louvet C; Bouché O; Malka D
Eur J Cancer; 2024 May; 202():114000. PubMed ID: 38493667
[TBL] [Abstract][Full Text] [Related]
18. Rational development of combination therapies for biliary tract cancers.
Harding JJ; Khalil DN; Fabris L; Abou-Alfa GK
J Hepatol; 2023 Jan; 78(1):217-228. PubMed ID: 36150578
[TBL] [Abstract][Full Text] [Related]
19. Biliary tract cancer.
Søreide K; Dopazo C; Berrevoet F; Carrion-Alvarez L; Diaz-Nieto R; Andersson B; Stättner S;
Eur J Surg Oncol; 2024 Jun; ():108489. PubMed ID: 38902180
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
Wilbur HC; Soares HP; Azad NS
Hepatology; 2024 Jan; ():. PubMed ID: 38266282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
